Show simple item record

dc.contributor.authorGonzález Salvatierra, Sheila
dc.contributor.authorMartínez Heredia, Luis
dc.contributor.authorMuñoz Torres, Manuel Eduardo 
dc.contributor.authorRiquelme Gallego, Blanca
dc.identifier.citationGonzález-Salvatierra, S.; García-Fontana, C.; Andújar-Vera, F.; Grau-Perales, A.B.; Martínez-Heredia, L.; Avilés-Pérez, M.D.; Hayón-Ponce, M.; Iglesias-Baena, I.; Riquelme-Gallego, B.; Muñoz-Torres, M.; et al. Osteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patients. J. Clin. Med. 2021, 10, 2209.
dc.description.abstractOsteoglycin (OGN) could be a biomarker of mild kidney function impairment in type 2 diabetes (T2D). Our study aimed to determine the association between serum OGN and impaired kidney function risk in T2D patients and to analyze its potential role as an estimator of kidney disturbances in this population. This cross-sectional study included 147 T2D patients (65 ± 8 years, 58.5% males), and 75 healthy controls (63 ± 10 years, 36% males). Circulating OGN levels were determined by ELISA. Linear regression modeling was performed to determine the variables influencing circulating OGN, and an ROC curve was plotted to assess the usefulness of OGN as an estimator of diabetic kidney disease risk. Circulating OGN was significantly increased in T2D patients compared to controls (18.41 (14.45–23.27) ng/mL vs. 8.74 (7.03–12.35) ng/mL; p < 0.001). We found a progressive increase in serum OGN according to the severity of kidney impairment in T2D patients (normal kidney function: 16.14 (12.13–20.48) ng/mL; mildly impaired kidney function: 19.15 (15.78–25.90) ng/mL; moderate impaired kidney function: 21.80 (15.06–29.22) ng/mL; p = 0.006). Circulating OGN was an independent estimator of mildly impaired kidney function risk in T2D patients. We suggest that serum OGN could act as an albuminuria-independent biomarker of incipient kidney dysfunction in T2D patients.es_ES
dc.description.sponsorshipJunta de Andalucía grants (PI-0207-2016 and PI0268-2019)es_ES
dc.description.sponsorshipInstituto de Salud Carlos III grants (PI18-00803 and PI18-01235)es_ES
dc.description.sponsorshipEuropean Regional Development Fund (FEDER)es_ES
dc.description.sponsorshipInstituto de Salud Carlos III (FI19/00118; CD20/00022)es_ES
dc.rightsAtribución 3.0 España*
dc.subjectDiabetic kidney diseasees_ES
dc.subjectKidney function impairmentes_ES
dc.subjectType 2 diabeteses_ES
dc.titleOsteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patientses_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España